VEGF

[Scientific Reports] Researchers reported soluble Robo4 was the product of constitutive ectodomain shedding of endothelial cell surface Robo4 by disintegrin metalloproteinases ADAM10 and ADAM17 and acted to inhibit angiogenic Slit3 signaling.

[Cell Death & Disease] Macrophage-derived VEGF activated CD34+ progenitor cells within the adventitial vasculogenic zone to differentiate into CD31+ endothelial cells.

[Regenerative Medicine] A murine model of a skin wound was treated with a combination of extract of astragalus and exosomes of MSCs. CD11b+ and CD45 macrophages were detected and levels of cytokines were tested.

[Elpiscience Biopharmaceuticals, Inc.] Elpiscience Biopharmaceuticals, Inc. announced that the first patient has been dosed in a Phase I/II clinical study, evaluating the safety, tolerability, preliminary anti-tumor efficacy and pharmacokinetics of ES104, a bispecific antibody that simultaneously blocks the DLL4 and VEGF-A signaling pathways that are critical to angiogenesis and tumor vascularization.

[Science Advances] Researchers performed multiplex ELISA angiogenesis arrays on aqueous fluid from proliferative diabetic retinopathy patients who responded inadequately to anti-VEGF therapy and/or pan-retinal laser photocoagulation and identified plasminogen activator inhibitor-1 (PAI-1).

[Journal of Ethnopharmacology] Shuxuetong injection promoted angiogenesis and improved function recovery in hindlimb ischemia mice by regulation of VEGF-A/platelet-derived growth factor.